Alpha Tau Medical (DRTS) Competitors

Alpha Tau Medical (NASDAQ:DRTS) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.

Does the media favor DRTS or EMBC?

In the previous week, Alpha Tau Medical and Alpha Tau Medical both had 5 articles in the media. Embecta's average media sentiment score of 1.38 beat Alpha Tau Medical's score of 0.47 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in DRTS or EMBC?

Alpha Tau Medical received 20 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 72.41% of users gave Alpha Tau Medical an outperform vote while only 5.56% of users gave Embecta an outperform vote.

Company	Underperform	Outperform
Alpha Tau Medical	Outperform Votes 21 72.41%	Underperform Votes 8 27.59%
Embecta	Outperform Votes 1 5.56%	Underperform Votes 17 94.44%

Which has better earnings & valuation, DRTS or EMBC?

Embecta has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$29.16M	-$0.45	-6.91
Embecta	$1.08B	0.67	$78.30M	$0.90	13.72

Do analysts rate DRTS or EMBC?

Alpha Tau Medical currently has a consensus target price of $8.00, suggesting a potential upside of 157.23%. Embecta has a consensus target price of $20.33, suggesting a potential upside of 64.64%. Given Alpha Tau Medical's stronger consensus rating and higher possible upside, research analysts plainly believe Alpha Tau Medical is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Embecta	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do insiders & institutionals believe in DRTS or EMBC?

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 0.4% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more risk & volatility, DRTS or EMBC?

Alpha Tau Medical has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Embecta has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.

Is DRTS or EMBC more profitable?

Embecta has a net margin of 5.25% compared to Alpha Tau Medical's net margin of 0.00%. Embecta's return on equity of -19.22% beat Alpha Tau Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-38.62%	-29.89%
Embecta	5.25%	-19.22%	11.92%

Summary

Embecta beats Alpha Tau Medical on 10 of the 16 factors compared between the two stocks.